Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0980
+0.0130 (15.29%)
At close: Feb 10, 2026
Market Cap55.77M -54.8%
Revenue (ttm)n/a
Net Income-35.72M
EPS-0.07
Shares Out569.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume644,943
Average Volume2,212,569
Open0.0840
Previous Close0.0850
Day's Range0.0840 - 0.0980
52-Week Range0.0770 - 0.3190
Beta1.04
RSI32.78
Earnings DateFeb 26, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements